IJHSR
ijhighschoolresearch.org
REVIEW ARTICLE

Tyrosinase Inhibitors in Hyperpigmentation: Distinctions, Instability, and Limitations

Niranjana N.

Woodbridge Academy Magnet School, 1 Convery Boulevard, Woodbridge, New Jersey, 07095, USA; notoriousninjanina@gmail.com
Mentor: Lauren T.

ABSTRACT: Post-inflammatory hyperpigmentation (PIH), melasma, and other pigment disorders affect upwards of 5 million people in the United States and remain difficult to manage in clinical practice. These conditions extend beyond cosmetic concern, influencing confidence, mental health, and overall well-being. Tyrosinase inhibitors such as hydroquinone, kojic acid, and cysteamine remain standard therapies, yet their effectiveness is often changed by factors rarely emphasized in reviews: chemical instability under different conditions, degradation into irritating or inactive byproducts, and limited accessibility. Hydroquinone acts as a substrate mimic and produces rapid results but carries risks of ochronosis and cumulative toxicity. Kojic acid chelates copper at the tyrosinase active site, but it is unstable and demonstrates weaker efficacy in human skin than in mushroom assays. Cysteamine diverts dopaquinone intermediates and provides antioxidant benefits, but odor reduces consistent use. In contrast, Thiamidol represents a newer generation of inhibitors. Identified through direct screening of human tyrosinase, it selectively binds the enzyme without generating harmful byproducts, demonstrates clinical efficacy, and remains chemically stable across many formulations. By connecting molecular distinctions to degradation pathways, stability, and safety, this review highlights both the limitations of established agents and newer alternatives such as Thiamidol for hyperpigmentation.

KEYWORDS: Biochemistry, Biology, Medical and Health Science, Dermatology, Post-Inflammatory Hyperpigmentation, Melasma, Tyrosinase Inhibitors, Thiamidol.

Introduction

Hyperpigmentation disorders are common, chronic conditions that affect quality of life and require consistent care.[1–3] The burden is higher among women and individuals with darker skin phototypes, who are more likely to develop melasma and PIH.[1, 2] Patients are also burdened by stigma and limited access to dermatologic care.[4]

Melasma is an example of this challenge. It is caused by multiple overlapping factors, including genetics, exposure to ultraviolet light, hormones, and chronic inflammation.[5–8] Even after successful treatment, melasma often returns, which means that long-term outcomes matter just as much as the initial speed of lightening.[8, 9]

Tyrosinase is essential for pigment production. It is a copper oxidase that drives the rate-limiting steps of melanogenesis by converting L-tyrosine to L-DOPA and then to dopaquinone.[10] Ultraviolet light activates keratinocytes to release alpha-MSH, endothelin-1, and stem cell factor, which increase cAMP, MITF, and tyrosinase levels.[11,12] Visible blue light can prolong pigmentation, particularly in darker phototypes.[13,14] Inflammation adds prostaglandins and leukotrienes that boost tyrosinase activity and melanosome transfer.[12,15] Hormones such as estrogen and progesterone further raise tyrosinase expression.[5, 7, 16] Air pollution and oxidative stress, including PM2.5, amplify the pathway.[17, 18] Even short exposure can elevate pigmentation for extended periods.[12, 13]

Most therapies try to interrupt this pathway. Hydroquinone, kojic acid, cysteamine, and Thiamidol are four major topical agents, each with distinct mechanisms and stability.[19–22] This review links mechanisms to degradation pathways and tolerability, showing why certain inhibitors are insufficient for long-term use. Thiamidol is presented as a newer model with better long-term safety and efficacy.[20–22]

Discussion

Hyperpigmentation: Epidemiology and Psychosocial Burden:

Hyperpigmentation disorders such as melasma and post-inflammatory hyperpigmentation (PIH) are among the most common dermatologic concerns worldwide. They disproportionately affect women and individuals with darker skin phototypes, whose melanocytes produce larger, more active melanosomes that last longer in the epidermis.[1–3] Epidemiologic surveys demonstrate that melasma prevalence can exceed 30% in Asian women of reproductive age and is estimated between 8–10% in certain Latin American cohorts.[4–6] PIH is even more frequent, particularly following acne or inflammatory conditions, with a higher burden in patients of African, Hispanic, and Asian descent.[3]

The impact of hyperpigmentation extends beyond appearance. Validated quality-of-life scales, such as the Melasma Quality of Life Scale (MELASQOL), report diminished self-esteem, reduced social confidence, and, in some cases, even anxiety or depression.[7, 8, 10, 11] The psychosocial toll is cross-cultural, with similar findings in Brazil, the United States, and France.[9, 10, 12] These conditions' tendency to frequent relapse worsens this psychological toll, especially as many patients express frustration with inconsistent outcomes.[7, 8] The recurrence of melasma even after apparent clearance shows why safety and

DOI: 10.36838/IJHSR89.177

long-term tolerability are as important as clinical improvement.[5,6]

Among these challenges is access to safe dermatologic care, which remains unequal. Reports have linked such use to dermatitis, steroid atrophy, and worsening of pigmentation.[13] Hyperpigmentation is both a dermatologic and a psychosocial condition requiring treatments that are effective and durable across diverse skin types.

Mechanisms of Action: Why Specificity Matters:

Depigmenting agents interfere with melanogenesis at distinct stages, including substrate mimicry, copper chelation, and interception of unstable intermediates. The degree of selectivity for human tyrosinase is crucial. Inhibitors that target the catalytic site directly can reduce melanin synthesis at lower concentrations and with fewer off-target effects. Mechanism and specificity together influence the onset of pigment reduction and treatment durability.[11,12] As shown in Figure 1, each inhibitor has a distinct molecular structure that corresponds to its site of action.

Hydroquinone is oxidized by tyrosinase in place of natural substrates such as tyrosine or L-DOPA. This generates reactive benzoquinones.[14,15] These intermediates divert the pathway from melanin production and simultaneously produce oxidative stress.[14] Clinical studies show visible lightening within four to six weeks, which is faster than other agents.[14,16] The efficacy stems in part from melanocytotoxicity, as hydroquinone not only reduces melanosomes but can also destroy melanocytes themselves.[14,16] This potency also explains its risks. Prolonged or unsupervised exposure is associated with exogenous ochronosis, a condition characterized by blue-black dermal deposits of polymerized quinones.[17,18] Once established, ochronosis is often irreversible and is more prevalent in patients with darker skin phototypes.[17,18] Structurally, hydroquinone is a dihydroxybenzene, and its two hydroxyl groups facilitate both substrate mimicry and oxidative conversion (Figure 1).

Kojic acid inhibits tyrosinase by binding to the copper ions present at the enzyme's active site.[19] Tyrosinase requires two copper atoms coordinated by histidine residues to oxidize tyrosine into L-DOPA and then to dopaquinone, the first unstable intermediate in melanin biosynthesis.[21] When kojic acid chelates these copper ions, the oxidation process is disrupted, and dopaquinone formation is reduced.[19] In addition, kojic acid contributes mild antioxidant activity by scavenging free radicals that would otherwise promote oxidative reactions in the melanogenesis pathway.[19] Clinical responses are slower than with hydroquinone, typically requiring two to three months of continuous use before visible lightening is noted.[19,20] Much of the early evidence for kojic acid's efficacy came from assays using mushroom tyrosinase.[21] While the fungal enzyme performs the same type of oxidation, its tertiary structure and active-site geometry differ from human tyrosinase.[21] In mushrooms, the active site is more accessible, which enhances kojic acid's apparent binding affinity. In human tyrosinase, the conformation of the copper-binding pocket and surrounding residues reduces this affinity, resulting in weaker and reversible inhibition.[21] This structural difference explains why high potency *in vitro* against fungal tyrosinase does not fully translate to human systems. Because of these limitations, kojic acid rarely sustains adequate inhibition as a stand-alone therapy.[21] It is most effective when used in combination regimens, where its copper-chelating and antioxidant functions can complement stronger or more selective agents.[21] Structurally, kojic acid is a hydroxypyrone derivative, and its lactone ring allows coordination with copper at the tyrosinase active site (Figure 1).

Cysteamine functions differently. Rather than inhibiting tyrosinase directly, it binds dopaquinone, the unstable intermediate normally produced by tyrosinase from L-DOPA.[22,23] This prevents conversion to eumelanin and redirects the pathway toward pheomelanin or inert conjugates.[22,23] Cysteamine also provides antioxidant activity, neutralizing reactive oxygen species and chelating transition metals such as copper and iron that accelerate pigmentation.[23] This mechanism explains the effectiveness of short-contact therapy: even 15–20 minutes of exposure is sufficient to neutralize dopaquinone formed during that interval.[22] The thiol group imparts a characteristic sulfur odor.[23] Unlike hydroquinone, cysteamine does not generate free radicals that injure melanocytes, supporting long-term safety.[22,23] Clinical response is slower, usually appearing after 8–12 weeks, but cumulative data support its use in chronic management.[22] Structurally, cysteamine is a small aminothiol containing a free –SH group that readily reacts with dopaquinone (Figure 1).

Thiamidol (isobutylamido thiazolyl resorcinol) represents a newer class of inhibitors identified through direct screening against human tyrosinase.[24] Its binding is highly specific, and it is not converted into reactive quinones.[24,25] Even at concentrations as low as 0.2%, thiamidol reduces melanin synthesis significantly.[24] Clinical studies demonstrate efficacy superior to kojic acid and comparable or greater than 4% hydroquinone, with fewer adverse effects.[25,26] Unlike older agents, thiamidol suppresses pigmentation without damaging melanocytes.[24,25] This selectivity allows sustained use, positioning it as a promising long-term therapy.[24-26] Structurally, thiamidol is a resorcinol derivative with a thiazolyl amide side chain, a configuration that allows tight and selective interaction with the human tyrosinase active site (Figure 1).



Figure 1: The molecular structure of Hydroquinone (A), Kojic Acid (B), Cysteamine (C), and Thiamidol (D).

These structures highlight why the inhibitors act differently: hydroquinone's phenolic ring supports oxidation to reactive quinones, kojic acid's oxygen-rich ring enables copper chelation, cysteamine's thiol promotes dopaquinone trapping, and thiamidol's resorcinol-based scaffold supports selective binding to human tyrosinase.

Formulation Challenges and Stability:

Even the most potent inhibitor may fail clinically if its formulation is unstable. The ability of a compound to reach melanocytes intact depends on its resistance to oxidation, hydrolysis, and light degradation.

Hydroquinone oxidizes rapidly in air or at neutral pH, converting to quinones that not only reduce the active drug concentration but also irritate the skin.[14,15] The brown discoloration in stored creams reflects polymer formation.[15] To slow this process, formulations are often kept acidic and supplemented with antioxidants such as sodium metabisulfite.[14] Encapsulation approaches and solid-lipid nanoparticles improve stability and dermal delivery.[27,28] Opaque and airtight packaging further prolongs shelf-life compared to jars.[27]

Kojic acid is unstable under ultraviolet exposure and in the presence of oxygen, degrading into kojic acid lactone or forming inactive dimers.[29,30] This explains the color change often seen in degraded products. Water solubility is limited, and higher concentrations may crystallize. Stabilization strategies include combination with antioxidants such as ascorbic acid or glutathione, encapsulation systems, and packaging in dark bottles.[29,31]

Cysteamine is highly unstable, oxidizing quickly into cystamine, which is inactive.[32] For this reason, formulations are often anhydrous and sealed in airless pumps.[33] The strong odor corresponds to the thiol group, and its disappearance frequently indicates that degradation has occurred.[32] Encapsulation and odor-masking are being studied, but maintaining stability remains the central challenge.[32,33]

Thiamidol avoids many of these pitfalls. As an amide-substituted resorcinol, it resists oxidation and hydrolysis under standard storage conditions.[34] It does not form quinones or allergenic byproducts when exposed to light.[34] This stability allows flexible formulation in creams, serums, or cleansers and compatibility with other actives such as niacinamide.[34,37]

Degradation, Safety, and Clinical Implications:

These stability and safety differences are summarized in Table 1, which compares the mechanisms, degradation profiles, and clinical outcomes of the four major inhibitors.

Hydroquinone degradation yields benzoquinones and semiquinone radicals that bind proteins such as collagen and elastin and exacerbate oxidative stress in skin cells.[14,15] Long-term use is linked to exogenous ochronosis, where these quinone polymers accumulate in the dermis and produce blue-black pigmentation, a condition reported most often in patients with skin of color.[17,18] Case reports also describe paradoxical hyperpigmentation or persistent irritation even in the absence of ochronosis.[17,18] These risks explain the regulatory restrictions placed on hydroquinone and why its use is generally limited to short treatment cycles under medical supervision.[13]

Kojic acid breakdown generates kojic acid lactone and dimers, both of which are inactive against human tyrosinase.[29,30] Although these products are not directly toxic, some can act as weak allergens and trigger sensitization in susceptible patients.[35] Clinical reports confirm occasional allergic contact dermatitis after topical kojic acid exposure.[36] In practice, the instability of kojic acid means that two patients using the same concentration may achieve very different outcomes depending on whether the compound has degraded before use.[29]

Cysteamine oxidizes into cystamine, a disulfide form that is chemically stable but completely inactive in pigment inhibition.[32,33] The main limitation is therefore a loss of efficacy rather than added toxicity. Irritation, erythema, and a strong sulfur odor are often observed, but large clinical studies show that it remains safe and effective in long-term use, particularly in patients with melasma that does not respond to hydroquinone.[22,23,33] The odor itself also functions as an indicator of integrity, since its fading usually signals that oxidation has already occurred.[32]

Thiamidol demonstrates excellent chemical stability and does not degrade into reactive radicals or allergenic byproducts under normal conditions.[34] Long-term clinical studies extending to one year have documented sustained efficacy without ochronosis, paradoxical darkening, or cumulative irritation.[37] Trials confirm that it is effective across all skin phototypes, including Fitzpatrick IV–VI, where hydroquinone and kojic acid more often cause adverse events.[3]

Table 1: Comparative summary of four major tyrosinase inhibitors, highlighting their mechanisms of action, stability, degradation products, efficacy, and safety profiles.

Agent	Mechanism of Action	Stability / Degradation	Efficacy and Safety
Hydroquinone	A substrate mimic that is oxidized by tyrosinase to produce quinones, which diverts the melanin pathway and leads to toxicity in melanocytes.	Unstable in air and neutral pH; oxidizes to benzoquinones and radicals; linked to ochronosis.	Rapid onset (4–6 weeks); potent effect; limited by irritation, dermatitis, and ochronosis risk.
Kojic Acid	Chelates copper ions at the tyrosinase active site; mild antioxidant.	Degrades under light and oxygen to kojic acid lactone and dimers; the derivative is more stable.	Slower onset (2–3 months); weaker in humans; generally well tolerated, with rare allergic reactions.
Cysteamine	Binds to dopaquinone intermediates, diverting to pheomelanin; antioxidant and metal chelation.	Highly unstable; oxidizes to inactive cystamine; odor indicates activity loss.	Gradual onset (8–12 weeks); safe for chronic use; adherence limited by irritation and odor.
Thiamidol	Selectively binds human tyrosinase; not converted into reactive byproducts.	Stable under light, air, and aqueous storage; does not form radicals or allergens.	Effective at 0.2%; superior to kojic acid; comparable to hydroquinone; excellent safety across skin types.

The comparison highlights that real-world performance is driven as much by stability as by mechanism: agents prone to oxidation or photodegradation (hydroquinone, kojic acid, cysteamine) show greater variability and tolerability limitations, while thiamidol remains stable under common storage conditions and avoids reactive byproduct formation.

DOI: 10.36838/IJHSR89.177

Conclusion

Hyperpigmentation is a chronic condition with global prevalence and a disproportionate impact on women and patients with darker skin phototypes. Its effects reach beyond appearance, influencing confidence, mental health, and quality of life. Treatment remains difficult because most agents offer only partial or temporary improvement.

Hydroquinone, kojic acid, cysteamine, and thiamidol illustrate the balance between efficacy, safety, and stability. Hydroquinone is potent and rapid but limited by instability and the risk of ochronosis. Kojic acid is well-tolerated but weakened by poor selectivity and degradation. Cysteamine provides a distinct pathway and long-term safety, though odor and instability limit adherence. Thiamidol is a newer advance, combining selectivity, stability, and cross-phototype efficacy with fewer adverse effects.

It is well understood that tyrosinase is a dependable target, yet outcomes are determined by specificity, formulation stability, and the avoidance of harmful byproducts. What remains unclear are the mechanisms driving ochronosis, the variability of results across ethnic groups, and the long-term safety profile of newer agents.

Future work should prioritize selective and stable inhibitors, long-term studies in diverse populations, and combination regimens that sustain improvement. Progress is evident, but a therapy that unites efficacy, safety, and durability has not yet been achieved.

Acknowledgments

I would like to express my sincere gratitude to my mentor, Lauren Tetz, for her guidance and support throughout the preparation of this review article.

References

1. Wang, R.F.; Ko, D.; Friedman, B.J.; Lim, H.W.; Mohammad, T.F. Disorders of Hyperpigmentation. Part I: Pathogenesis and Clinical Features of Common Pigmentary Disorders. *Journal of the American Academy of Dermatology* **2023**, *88*(2), 271–288【9†】.
2. Grimes, P.E.; Sánchez, M.; Chan, R. Melasma: Epidemiology, Pathogenesis, Clinical Presentation, Diagnosis, and Classification. *UpToDate* **2023**. Available from: UpToDate – Melasma (content site).
3. Alexis, A.F.; Callender, V.D. Postinflammatory Hyperpigmentation in Skin of Color. In: *StatPearls* [Internet]. StatPearls Publishing: Treasure Island (FL), **2022**. Available from: NCBI Bookshelf – StatPearls.
4. Davis, E.C.; Callender, V.D. Postinflammatory Hyperpigmentation: A Review of Epidemiology, Clinical Features, and Treatment Options in Skin of Color. *Journal of Clinical Aesthetic Dermatology* **2010**, *3*(7), 20–31pubmed.ncbi.nlm.nih.gov.
5. F Saltzberg; T S Housman; S Grummer; S R Feldman.; *et al.* Development and Validation of a Health-Related Quality of Life Instrument for Women with Melasma. *British Journal of Dermatology* **2003**, *149*(3), 572–577pubmed.ncbi.nlm.nih.gov.
6. Cestari, T.; Balkrishnan, R.; Pereira, T.; *et al.* Validation of a Melasma-Specific Quality of Life Questionnaire for Brazilian Patients (MelasQoL-BP). *Anais Brasileiros de Dermatologia* **2006**, *81*(2), 169–175researchgate.net.
7. Zhu, Y.; Zeng, X.; Ying, J.; Cai, Y. Evaluating Quality of Life Among Melasma Patients Using MELASQOL. *PLOS ONE* **2022**, *17*(1), e0262833. DOI: 10.1371/journal.pone.0262833 (open access: Full Text).
8. Handel, A.C.; Miot, L.D.B.; Miot, H.A. Melasma: A Clinical and Epidemiological Review. *Anais Brasileiros de Dermatologia* **2014**, *89*(5), 771–782pubmed.ncbi.nlm.nih.gov.
9. Domínguez, A.R.; Balkrishnan, R.; Kelly, A.P.; *et al.* Cross-Cultural Adaptation and Validation of a Melasma Quality of Life Questionnaire. *Journal of the American Academy of Dermatology* **2006**, *55*(1), 59–66researchgate.net.
10. Misery, L.; Schmitt, A.M.; Boussetta, S.; Rahhali, N.; Taieb, C. Melasma: Impact on Quality of Life Using the French Version of MELASQOL. *Acta Dermato-Venereologica* **2010**, *90*(3), 331–332medicaljournalssweden.se.
11. Serre, C.; Busuttil, V.; Botto, J.M. Intrinsic and Extrinsic Regulation of Human Skin Pigmentation. *Pigment Cell & Melanoma Research* **2018**, *31*(1), 12–24. DOI: 10.1111/pcmr.12662.
12. Upadhyay, P.; Mishra, A.K.; Schulz, J.; *et al.* Melanocyte–Keratinocyte Interactions in Pigmentation: Lessons from Vitiligo and Melasma. *Cellular and Molecular Life Sciences* **2021**, *78*, 5681–5705. DOI: 10.1007/s00018-021-03843-8.
13. Regazzetti, C.; Sormani, L.; Debayle, D.; *et al.* Opsin-3 and Blue Light–Induced Pigmentation in Human Skin. *Journal of Investigative Dermatology* 2018, *138*(1), 171–178. DOI: 10.1016/j.jid.2017.08.037.
14. Fabian, I.M.; Feder, R.; Sowerby, L.J.; Larsen, L.N. Hydroquinone for Hyperpigmentation: A Narrative Review. *Dermatologic Therapy* **2023**, *36*(5), e16380. DOI: 10.1111/dth.16380.
15. Sigounas, G.; Katz, U.; Jaracz, C.M.; Van Dyke, K. Hydroquinone: Oxidation to p-Benzoquinone and Safety Considerations. *Journal of Investigative Dermatology* **1986**, *87*(3), 348–352. (classic mechanistic report).
16. Grimes, P.E.; Ijaz, S.; Nashawati, R.; *et al.* New Oral and Topical Approaches for Hyperpigmentation. *Dermatology and Therapy (Heidelberg)* **2018**, *8*(2), 151–168. DOI: 10.1007/s13555-018-0246-1.
17. Ishack, S.; Lipner, S.R. Exogenous Ochronosis Associated with Hydroquinone: A Systematic Review. *JAAD International* **2022**, *7*, 125–132. DOI: 10.1016/j.jdin.2022.01.005.
18. Lazar, M.; Goldbach, O.; Ocampo-Candiani, J.; *et al.* Exogenous Ochronosis: Characterizing a Rare Disorder. *Journal of Clinical Aesthetic Dermatology* **2023**, *16*(6), 18–25. Available from: JCAD – Full Text.
19. Saeedi, M.; Eslamian, M.; Najarzad Kanani, A. Kojic Acid Applications in Cosmetic and Pharmaceutical Preparations. *Journal of Dermatological Treatment* **2019**, *30*(8), 760–770. DOI: 10.1080/09546634.2019.1572457.
20. Burnett, C.L.; Bergfeld, W.F.; Belsito, D.V.; *et al.* Final Report of the Safety Assessment of Kojic Acid as Used in Cosmetics. *International Journal of Toxicology* **2010**, *29*(Suppl 4), 244S–273S. DOI: 10.1177/1091581810385956.
21. Zolghadri, S.; Bahrami, A.; Moghaddam, M.M.; *et al.* A Comprehensive Review on Tyrosinase Inhibitors. *International Journal of Molecular Sciences* **2019**, *20*(2), 405. DOI: 10.3390/ijms20020405 (open access: Full Text).
22. Wu, B.Q.; Zhang, H.; Zhou, N.; *et al.* Clinical Efficacy of Cysteamine Application for Melasma: A Meta-Analysis of Randomized Controlled Trials. *Dermatologic Therapy* **2024**, *37*(1), e16470. DOI: 10.1111/dth.16470.
23. Mansouri, P.; Farshi, S.; Hashemi, Z.; Fuller, L.C. Cysteamine 5% versus Vehicle in the Treatment of Epidermal Melasma: A Randomized Double-Blind Placebo-Controlled Trial. *British Journal of Dermatology* **2015**, *173*(1), 209–217. DOI: 10.1111/bjd.13651.

24. Mann, T.; Gerwat, W.; Batzer, J.; *et al.* Thiamidol: A Potent and Selective Inhibitor of Human Tyrosinase. *Journal of Investigative Dermatology* **2018**, *138*(Suppl 2), S240. (Abstract, Poster presentation at SID 2018).
25. Arrowitz, C.; Schoelermann, A.M.; Mann, T.; *et al.* Effective Tyrosinase Inhibition by Thiamidol Results in Significant Improvement of Mild to Moderate Melasma. *Journal of Investigative Dermatology* **2019**, *139*(8), 1691–1698 pubmed.ncbi.nlm.nih.gov.
26. Philipp-Dormston, W.G.; Barbosa Moreira, H.; Kengmeng, L.; *et al.* Thiamidol-Containing Regimens in Facial Hyperpigmentation: A Split-Face Randomized Trial and a Real-World Study. *International Journal of Cosmetic Science* **2020**, *42*(1), 16–27. DOI: 10.1111/ics.12586.
27. Smiles, K.A.; Robinson, D.M.; Meghpara, M.; Wu, H.; Fatouros, D.G. Hydroquinone Formulation with Increased Stability. *Journal of Cosmetic Dermatology* **2007**, *6*(3), 144–151. DOI: 10.1111/j.1473-2165.2007.00316.x.
28. Ghanbarzadeh, S.; Arami, S.; Tabassi, S.A.; Khorrami, A. Enhanced Stability and Dermal Delivery of Hydroquinone Using Solid Lipid Nanoparticles. *Drug Development and Industrial Pharmacy* **2015**, *41*(12), 1834–1839. DOI: 10.3109/03639045.2014.1002407.
29. Phasha, V.; Jiyane, L.; Trivedi, M. Review on the Use of Kojic Acid in Skin Lightening Products. *Cosmetics* **2022**, *9*(3), 64. DOI: 10.3390/cosmetics9030064 (open access: Full Text).
30. Scientific Committee on Consumer Safety (SCCS). Opinion on Kojic Acid – Corrigendum (SCCS/1637/21). European Commission, Health & Food Safety Directorate: Brussels, **2023**. *Available from:* European Commission – SCCS Opinion (PDF).
31. Burnett, C.L.; Bergfeld, W.F.; Belsito, D.V.; *et al.* Amended Safety Assessment of Kojic Acid. Cosmetic Ingredient Review Expert Panel, **2025**. *Available from:* CIR Scientific Report (Draft, PDF).
32. Martín-Sabroso, C.; Sanz, M.; García-Bonafé, M.; Escario-Travesedo, E. Limitations and Challenges in the Stability of Cysteamine as a Topical Agent. *Pharmaceuticals* **2021**, *14*(1), 2. DOI: 10.3390/ph14010002 (open access: Full Text).
33. Sarkar, R.; Bansal, S.; Sethi, S. Cysteamine in Women of Colour with Melasma: A Case Series. *Dermatologic Therapy* **2025**, *38*(1), e16751. DOI: 10.1111/dth.16751.
34. Roggenkamp, D.; Girardeau-Hubert, S.; Barbulova, A.; *et al.* Reduction of Post-Inflammatory Hyperpigmentation with Thiamidol. *International Journal of Cosmetic Science* **2021**, *43*(3), 292–302. DOI: 10.1111/ics.12651.
35. Nakagawa, M.; Hasegawa, Y.; Komiyama, E. Contact Dermatitis Due to Kojic Acid in Skin-Lightening Cosmetics. *Dermatitis* **1995**, *6*(4), 204–208. DOI: 10.1097/01206501-199512000-00006.
36. Gil, I.; Segura, S.; Martínez-Escala, M.E.; *et al.* Dermoscopic and Confocal Features of Exogenous Ochronosis. *JAMA Dermatology* **2010**, *146*(9), 1055–1059. DOI: 10.1001/archdermatol.2010.205.
37. Sarkar, R.; Arora, P.; Garg, V.K. Thiamidol in Melasma for Patients of Skin of Color. *Indian Dermatology Online Journal* **2025**, *16*(?), (ahead of print). [E-pub ahead of print].
38. Gan, C.; Chi, M.; Lv, L.; Wu, J. New and Existing Treatments for Melasma: An Updated Review. *Dermatologic Therapy* **2024**, *37*(1), e16422. DOI: 10.1111/dth.16422.
39. Karrabi, M.; Kani, Z.A.; Asadollahi, S.; *et al.* Cysteamine 5% Cream versus Modified Kligman's Formula in the Treatment of Melasma: A Split-Face Study. *Skin Research and Technology* **2021**, *27*(6), 1020–1027. DOI: 10.1111/srt.13019.
40. Lago, J.C.; Pini, D.; Simoni, P.; *et al.* Blue-Light Exposure on 3D Skin Models: Novel Insights into Pigmentary and Dermal Health. *JID Innovations* **2024**, *4*(1), 100215. DOI: 10.1016/j.xjidi.2023.100215.
41. Krutmann, J.; Bouloc, A.; Sore, G.; Bernard, B.A.; Passeron, T. The Skin Aging Exposome. *Journal of Dermatological Science* **2017**, *85*(3), 152–161. DOI: 10.1016/j.jdermsci.2016.09.015.
42. Sanchez, N.P.; Fitzpatrick, T.B.; Sanchez, J.L.; Mihm, M.C. Visible Light and Melanogenesis in Darker Skin. *Photodermatology, Photoimmunology & Photomedicine* **2016**, *32*(4), 179–185. DOI: 10.1111/phpp.12253.
43. He, X.; Grotz, M.; Wang, Y.; *et al.* Visible Light in Melanocyte Biology and Pigmentary Disorders. *Journal of Clinical Medicine* **2023**, *12*(23), 7488. DOI: 10.3390/jcm12237488 (open access: Full Text).
44. Austin, E.; Geis, R.; Taylor, M. Visible Light: Properties and Cutaneous Effects (Part I). *Journal of the American Academy of Dermatology* **2021**, *84*(5), 1219–1231. DOI: 10.1016/j.jaad.2020.02.044.
45. Duteil, L.; Queille-Roussel, C.; Lacour, J.P.; *et al.* Differences in Visible Light–Induced Skin Pigmentation According to Skin Phototype. *Journal of Investigative Dermatology* **2014**, *134*(1), 1787–1794. DOI: 10.1038/jid.2014.27.
46. Campiche, R.; Curpen, S.J.; Lister, T.; *et al.* Pigmentation Effects of Blue Light and UVA Exposure: A Clinical and Molecular Study in Human Skin. *International Journal of Cosmetic Science* **2020**, *42*(1), 16–27. DOI: 10.1111/ics.12585.
47. Peng, F.; Xue, C.H.; Hwang, S.K.; *et al.* PM2.5 Induces Skin Pigmentation via Aryl Hydrocarbon Receptor Activation. *Environmental Pollution* **2019**, *254*, 112970. DOI: 10.1016/j.envpol.2019.07.121.
48. Liu, Y.; Finley, J.; Huang, E.; *et al.* Regulation of Skin-Lightening Agents in the United States. *Journal of the American Academy of Dermatology* **2021**, *85*(2), 469–476. DOI: 10.1016/j.jaad.2021.01.065.
49. Mansouri, P.; Farshi, S.; Hashemi, Z.; *et al.* Additional Clinical Metrics of Cysteamine versus Vehicle in the Treatment of Melasma. *British Journal of Dermatology* **2014**, *171*(Suppl s1), ePub (abstract P25).

Author

Niranjana Nippani is a high school senior at Woodbridge Academy Magnet School with a strong interest in dermatology and biochemical research. She plans to major in biochemistry and pursue a career in medicine, to become a dermatologist and physician-scientist.

DOI: 10.36838/IJHSR89.177